ARA-290, a peptide derived from the structure of erythropoietin, has gained attention for its potential therapeutic benefits in adults, particularly in the context of neuropathic pain and tissue repair. Clinical dosages of ARA-290 for adults typically range from 1 mg to 10 mg per day, administered subcutaneously or intravenously, depending on the specific clinical context and desired therapeutic outcomes (Schmidt et al., 2011; Heij et al., 2012).

The most frequently employed dosages in clinical trials have been around 1 mg administered once daily or two doses of 1 mg given on separate days during a week. In certain studies, doses have escalated up to 10 mg, particularly for uncontrolled neuropathic pain conditions where a more significant therapeutic effect is sought (Collino et al., 2015; Brines et al., 2014). The pharmacokinetics of ARA-290 indicate that the drug has a notably short half-life of approximately 2 minutes; thus, administration frequency is crucial to maintain therapeutic levels in the bloodstream without significant side effects typically related to erythropoietin (Culver et al., 2017; , Swartjes et al., 2014).

In adult patients, especially those suffering from diabetic neuropathy or acute inflammatory conditions, clinical trials have observed significant doses tailored to achieve optimal pain relief and physiological benefits. For example, treatments were so structured that ARA-290 was given at intervals designed to maintain plasma concentrations conducive to activating the innate repair receptor (IRR), which mediates its therapeutic effects (Joshi et al., 2014; , Gupta et al., 2021).

Ongoing investigations are consistently refining these dosages and administration routes, looking into optimal therapeutic ranges. As ARA-290 is investigated for its efficacy and safety across different adult populations, these dose adjustments will likely continue to evolve based on the pediatric response and individual patient needs (Sugaya et al., 2012; , Schulz et al., 2019).

In summary, current clinical applications of ARA-290 for adults show promising results at doses typically within the range of 1-10 mg per day, with ongoing research set to further elucidate the dosage guidelines across various indications.